MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100720 | Name: Pentostatin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pentostatin is classified as a purine analog, which is a type of antimetabolite. It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA. Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells. Pentostatin is used to treat hairy cell leukemia. It is given by intravenous infusion once every two weeks for three to six months. Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed. (Source: http://en.wikipedia.org/wiki/Pentostatin)

Chemical Structure

Pentostatin
Pentostatin
CAS#53910-25-1

Theoretical Analysis

MedKoo Cat#: 100720

Name: Pentostatin

CAS#: 53910-25-1

Chemical Formula: C11H16N4O4

Exact Mass: 268.1172

Molecular Weight: 268.27

Elemental Analysis: C, 49.25; H, 6.01; N, 20.88; O, 23.86

Price and Availability

Size Price Availability Quantity
10mg USD 250.00
20mg USD 450.00
50mg USD 850.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CI825; CI-825; CI 825; PD81565; PD-81565; PD 81565; covidarabine; deoxycoformycin; pentostatine. brand name: Nipent.
IUPAC/Chemical Name
(R)-3-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
InChi Key
FPVKHBSQESCIEP-KDXUFGMBSA-N
InChi Code
InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9-/m0/s1
SMILES Code
O[C@H]1C2=C(N([C@H]3O[C@H](CO)[C@@H](O)C3)C=N2)N=CNC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Pentostatin is a purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).   Pentostatin is used to treat hairy cell leukemia. It is given by intravenous infusion once every two weeks for three to six months. Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. Pentostatin is also used in CLL patients who have relapsed.      

Preparing Stock Solutions

The following data is based on the product molecular weight 268.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Paillassa J, Maitre E, Belarbi Boudjerra N, Madani A, Benlakhal R, Matthes T, Van Den Neste E, Cailly L, Inchiappa L, Bekadja MA, Tomowiak C, Troussard X. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group. Cancers (Basel). 2024 Jun 10;16(12):2185. doi: 10.3390/cancers16122185. PMID: 38927891; PMCID: PMC11201647. 2: Zeng J, Zhou Y, Lyu M, Huang X, Xie M, Huang M, Chen BX, Wei T. Cordyceps militaris: A novel mushroom platform for metabolic engineering. Biotechnol Adv. 2024 Sep;74:108396. doi: 10.1016/j.biotechadv.2024.108396. Epub 2024 Jun 19. PMID: 38906495. 3: Hershfield M, Tarrant T. Adenosine Deaminase Deficiency. 2006 Oct 3 [updated 2024 Mar 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301656. 4: Welch BM, Manso BA, Gwin KA, Lothert PK, Parikh SA, Kay NE, Medina KL. Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib. Front Oncol. 2023 Dec 4;13:1302038. doi: 10.3389/fonc.2023.1302038. PMID: 38111528; PMCID: PMC10725910. 5: Kovalenko I, Saleem T, Shah M, Seyedroudbari S, Golubykh K, Ali R, Mirza T, Laek B, Wahab A, Chattaraj A, Proskuriakova E, Garg C, Khan R. Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease. Adv Hematol. 2023 Dec 6;2023:9949961. doi: 10.1155/2023/9949961. PMID: 38094101; PMCID: PMC10718798. 6: Kumar Upadhyay A, Kumar M, Prasad A, Shekhar S, Singh R. A Case of Hairy Cell Leukemia Variant: Literature Analysis With Focus on Unmet Needs. Cureus. 2023 Oct 15;15(10):e47085. doi: 10.7759/cureus.47085. PMID: 38022018; PMCID: PMC10651060. 7: Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature. Curr Oncol. 2023 Nov 18;30(11):10007-10018. doi: 10.3390/curroncol30110727. PMID: 37999147; PMCID: PMC10669936. 8: Gao Q, Zhang D, Ding W, Zhai W, Gu C, Guo S. Effects of Exogenous Lanthanum Nitrate on the Active Substance Content and Antioxidant Activity of Caterpillar Medicinal Mushroom Cordyceps militaris (Ascomycetes). Int J Med Mushrooms. 2023;25(6):41-54. doi: 10.1615/IntJMedMushrooms.2023048203. PMID: 37522532. 9: Uba AI, Paradis NJ, Wu C, Zengin G. Phenolic compounds as potential adenosine deaminase inhibitors: molecular docking and dynamics simulation coupled with MM- GBSA calculations. Amino Acids. 2023 Dec;55(12):1729-1743. doi: 10.1007/s00726-023-03310-4. Epub 2023 Jul 30. PMID: 37517044. 10: Zhao H, Ding T, Chen Y, Yang W, Rao J, Liu D, Yi B. Arecoline aggravates acute ulcerative colitis in mice by affecting intestinal microbiota and serum metabolites. Front Immunol. 2023 Jul 10;14:1197922. doi: 10.3389/fimmu.2023.1197922. PMID: 37492574; PMCID: PMC10363717. 11: Wasifuddin M, Sabzposh H, Sun L, Wu R, Wang JC. Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion. J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231176223. doi: 10.1177/23247096231176223. PMID: 37219076; PMCID: PMC10214040. 12: Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA. Hairy Cell Leukemia: Where Are We in 2023? Curr Oncol Rep. 2023 Aug;25(8):833-840. doi: 10.1007/s11912-023-01419-z. Epub 2023 Apr 25. PMID: 37097545; PMCID: PMC10126561. 13: Raethong N, Thananusak R, Cheawchanlertfa P, Prabhakaran P, Rattanaporn K, Laoteng K, Koffas M, Vongsangnak W. Functional genomics and systems biology of Cordyceps species for biotechnological applications. Curr Opin Biotechnol. 2023 Jun;81:102939. doi: 10.1016/j.copbio.2023.102939. Epub 2023 Apr 17. PMID: 37075529. 14: Johnson AE, Raju AR, Jacob A, Hildebrandt GC. Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib. Front Oncol. 2023 Jan 12;12:1100577. doi: 10.3389/fonc.2022.1100577. PMID: 36713531; PMCID: PMC9877286. 15: Ahmad TY, Al Houri HN, Jomaa S, Assad W, Addeen SZ. Primary splenic T-cell/histiocyte-rich B-cell lymphoma in a patient with recurrent hairy cell leukemia: a case report. Oxf Med Case Reports. 2022 Nov 24;2022(11):omac123. doi: 10.1093/omcr/omac123. PMID: 36447474; PMCID: PMC9693827. 16: Janus A, Robak T. Hairy Cell Leukemia. In: Li W, editor. Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 3. PMID: 36395312. 17: Dimitrova D, Kanakry JA. Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning. Bone Marrow Transplant. 2022 Dec;57(12):1837-1838. doi: 10.1038/s41409-022-01819-y. Epub 2022 Sep 17. PMID: 36115868; PMCID: PMC9715427. 18: D'Addona M, Giudice V, Pezzullo L, Ciancia G, Baldi C, Gorrese M, Bertolini A, Campana A, Fresolone L, Manzo P, Zeppa P, Serio B, Selleri C. Hodgkin Lymphoma and Hairy Cell Leukemia Arising from Chronic Lymphocytic Leukemia: Case Reports and Literature Review. J Clin Med. 2022 Aug 10;11(16):4674. doi: 10.3390/jcm11164674. PMID: 36012912; PMCID: PMC9410146. 19: Gao S, Zhang W, Barrow SL, Iavarone AT, Klinman JP. Temperature-dependent hydrogen deuterium exchange shows impact of analog binding on adenosine deaminase flexibility but not embedded thermal networks. J Biol Chem. 2022 Sep;298(9):102350. doi: 10.1016/j.jbc.2022.102350. Epub 2022 Aug 4. PMID: 35933011; PMCID: PMC9483566. 20: Carey E, Ward N, Abdul-Hay M. Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report. J Med Case Rep. 2022 Jun 8;16(1):227. doi: 10.1186/s13256-022-03447-y. PMID: 35672859; PMCID: PMC9175501.